<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">N.N. Priorov Journal of Traumatology and Orthopedics</journal-id><journal-title-group><journal-title xml:lang="en">N.N. Priorov Journal of Traumatology and Orthopedics</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник травматологии и ортопедии им. Н.Н. Приорова</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-8678</issn><issn publication-format="electronic">2658-6738</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">623895</article-id><article-id pub-id-type="doi">10.17816/vto623895</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Clinical case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Features of the formation of bone regenerate and metabolism of bone formation markers in a patient with type 1 diabetes mellitus and diabetic neuroosteoarthropathy (Charcot foot)</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности формирования костного регенерата и метаболизм маркеров костеобразования у пациентки с сахарным диабетом 1 типа и диабетической нейроостеоартропатией (стопа Шарко)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5771-0973</contrib-id><contrib-id contrib-id-type="spin">7590-0446</contrib-id><name-alternatives><name xml:lang="en"><surname>Bardiugov</surname><given-names>Petr S.</given-names></name><name xml:lang="ru"><surname>Бардюгов</surname><given-names>Пётр Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук</p></bio><email>petrbardiugov@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2232-4765</contrib-id><contrib-id contrib-id-type="spin">4649-0765</contrib-id><name-alternatives><name xml:lang="en"><surname>Artemova</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Артёмова</surname><given-names>Екатерина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>artemova.ekaterina@endocrincentr.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4201-4577</contrib-id><contrib-id contrib-id-type="spin">5838-4366</contrib-id><name-alternatives><name xml:lang="en"><surname>Parshikov</surname><given-names>Mikhail V.</given-names></name><name xml:lang="ru"><surname>Паршиков</surname><given-names>Михаил Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), рrofessor</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор</p></bio><email>parshikovmikhail@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4322-6985</contrib-id><contrib-id contrib-id-type="spin">3258-4436</contrib-id><name-alternatives><name xml:lang="en"><surname>Yarygin</surname><given-names>Nikolay V.</given-names></name><name xml:lang="ru"><surname>Ярыгин</surname><given-names>Николай Николай</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), рrofessor, corresponding member of the Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, член-корр. РАН</p></bio><email>dom1971@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology Research Centre</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр эндокринологии</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian University of Medicine</institution></aff><aff><institution xml:lang="ru">Российский университет медицины</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Ilyinskaya Hospital</institution></aff><aff><institution xml:lang="ru">Ильинская больница</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-08-08" publication-format="electronic"><day>08</day><month>08</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-07-17" publication-format="electronic"><day>17</day><month>07</month><year>2024</year></pub-date><volume>31</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>381</fpage><lpage>394</lpage><history><date date-type="received" iso-8601-date="2023-11-27"><day>27</day><month>11</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-02-11"><day>11</day><month>02</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-Вектор</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-10-09"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/0869-8678/article/view/623895">https://journals.eco-vector.com/0869-8678/article/view/623895</self-uri><abstract xml:lang="en"><p><bold>Background</bold>: Surgical treatment of diabetic neuroosteoarthropathy is a complex area in traumatology — orthopedics not only because of severe biomechanical disorders and gross deformations of the distal segment of the lower limb, but also because these phenomena are accompanied by many disorders of the somatic status. Of particular importance is a pronounced decrease in bone mineral density. This case is intended to illustrate the features of the treatment of this pathology.</p> <p><bold>Clinical</bold><bold> </bold><bold>case</bold><bold> </bold><bold>description</bold><bold>:</bold> A clinical case of treatment of a 34-year-old young female patient with type 1 diabetes mellitus, development of diabetic neuroosteoarthropathy (Charcot foot), and aseptic necrosis of the talus of the right foot is presented. From 2019–2020 conservative and surgical treatment was carried out aimed at stopping the active stage of Charcot foot, correcting deformity and stabilizing the distal segment of the limb (calcaneotibial arthrodesis). A satisfactory treatment result was achieved, complete activation 8 months after the operation. However, in 2021 The patient suffered a closed low-energy fracture of the distal metaphysis of the right tibia. Regarding this episode, the patient comes in at the stage of consolidation of a displaced fracture and complaints of recurrence of varus deformity, even greater shortening of the limb, and swelling of the ankle joint. The fact of injury is denied, which allows us to regard the existing fracture of the tibia as pathological. In this regard, an operation was performed: osteotomy of the fibula and tibia in the area of consolidation of the pathological fracture in order to correct the deformity and compensate for the existing shortening of the limb due to the formation of a distraction regenerate. During the treatment, malnutrition and delayed formation of bone regenerate were noted, which required prolonged use of an external fixation device and specific drug therapy aimed at stimulating osteogenesis and improving bone mineral density. At the end of the course, there was an increase in the mineral density of the tissue, the density of the regenerate radiologically and laboratory (control of bone formation markers) and a satisfactory functional result.</p> <p><bold>CONCLUSION</bold><bold>: </bold>A successful result in this clinical case was achieved by combining orthopedic surgical and conservative treatment with specific drug therapy in a comorbid patient with reduced bone mineral density and a high probability of complications in a multidisciplinary approach.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Хирургическое лечение диабетической нейроостеоартропатии является сложным направлением в травматологии-ортопедии не только из-за тяжёлых нарушений биомеханики и грубых деформаций дистального сегмента нижней конечности, но и потому, что эти явления сопровождаются многими нарушениями соматического статуса. Особое значение имеет выраженное снижение минеральной плотности костной ткани. Данная работа призвана проиллюстрировать особенности лечения этой патологии.</p> <p>Описание клинического случая. Представлен клинический случай лечения молодой пациентки 34 лет с сахарным диабетом 1 типа, формированием диабетической нейроостеоартропатии (стопа Шарко), асептическим некрозом таранной кости правой стопы. В 2019–2020 гг. проведено консервативное и хирургическое лечение, направленное на купирование активной стадии стопы Шарко, коррекцию деформации и стабилизацию дистального сегмента конечности (пяточно-большеберцовый артродез). Были достигнуты удовлетворительный результат лечения, полная активизация через 8 месяцев после проведённой операции. Однако в 2021 г. пациентка получила закрытый низкоэнергетический перелом дистального метафиза правой большеберцовой кости. По поводу данного эпизода пациентка обращается за медицинской помощью на стадии консолидации перелома со смещением фрагментов и жалобами на рецидив варусной деформации, ещё большее укорочение конечности, отёк области голеностопного сустава. Факт травмы отрицала, что позволило расценивать имеющийся перелом большеберцовой кости как патологический. В связи с этим выполнена операция: остеотомия берцовых костей в зоне консолидации патологического перелома с целью коррекции деформации и компенсации имеющегося укорочения конечности за счёт формирования дистракционного регенерата. В процессе лечения отмечались гипотрофия, замедленное формирование костного регенерата, что потребовало пролонгированного применения аппарата внешней фиксации и проведения специфической медикаментозной терапии, направленной на стимуляцию остеогенеза. По окончании курса отмечено увеличение минеральной плотности ткани, плотности регенерата рентгенологически и лабораторно (контроль маркеров костеобразования) и получение удовлетворительного функционального результата.</p> <p><bold>Заключение.</bold> Успешный результат в данном клиническом случае достигнут при сочетании ортопедического хирургического и консервативного лечения со специфической медикаментозной терапией у коморбидного пациента со сниженной минеральной плотностью костной ткани, высокой вероятностью осложнений в условиях мультидисциплинарного подхода.</p></trans-abstract><kwd-group xml:lang="en"><kwd>case report</kwd><kwd>Charcot foot</kwd><kwd>osteoarthropathy</kwd><kwd>osteopenia</kwd><kwd>bone mineral density</kwd><kwd>calcaneotibial arthrodesis</kwd><kwd>bone regenerate</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>клинический случай</kwd><kwd>стопа Шарко</kwd><kwd>остеоартропатия</kwd><kwd>остеопения</kwd><kwd>минеральная плотность костной ткани</kwd><kwd>пяточно-большеберцовый артродез</kwd><kwd>костный регенерат</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes Metab Res Rev. 2024;40(3):e3646. doi: 10.1002/dmrr.3646</mixed-citation><mixed-citation xml:lang="ru">Wukich D.K., Schaper N.C., Gooday C., et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023) // Diabetes Metab Res Rev. 2024. Vol. 40, № 3. Р. е3646. doi: 10.1002/dmrr.3646</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AYu, et al. Algorithms of specialized medical care for patients with diabetes mellitus. Diabetes mellitus. 2023;26(2S):1–231. (In Russ). doi: 10.14341/DM13042</mixed-citation><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом // Сахарный диабет. 2023. Т. 26, № 2S. С. 1–231. doi: 10.14341/DM13042</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides. 1988;1(9):165–171. doi: 10.1016/0196-9781(88)90023-x</mixed-citation><mixed-citation xml:lang="ru">Bjurholm A., Kreicbergs A., Brodin E., Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone // Peptides. 1988. Vol. 1, № 9. Р. 165–171. doi: 10.1016/0196-9781(88)90023-x</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Bellinger DL, Lorton D, Felten SY, Felten DL. Innervation of lymphoid organs and implications in development, aging, and autoimmunity. International journal of immunopharmacology. 1992;3(14):329–344. doi: 10.1016/0192-0561(92)90162-e</mixed-citation><mixed-citation xml:lang="ru">Bellinger D.L. Lorton D., Felten S.Y., Felten D.L. Innervation of lymphoid organs and implications in development, aging, and autoimmunity // International journal of immunopharmacology. 1992. Vol. 3, № 14. Р. 329–344. doi: 10.1016/0192-0561(92)90162-e</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–317. doi: 10.1016/s0092-8674(02)01049-8</mixed-citation><mixed-citation xml:lang="ru">Takeda S., Elefteriou F., Levasseur R., et al. Leptin regulates bone formation via the sympathetic nervous system // Cell. 2002. Vol. 111, № 3. Р. 305–317. doi: 10.1016/s0092-8674(02)01049-8</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Moore RE, Smith CK II, Bailey CS, Voelkel EF, Tashjian AH Jr. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 1993;23(3):301–315. doi: 10.1016/S0169-6009(08)80105-5</mixed-citation><mixed-citation xml:lang="ru">Moore R.E., Smith C.K. II, Bailey C.S., Voelkel E.F., Tashjian A.H. Jr. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture // Bone Miner. 1993. Vol. 23, № 3. Р. 301–315. doi: 10.1016/S0169-6009(08)80105-5</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Togari A, Arai M, Mizutani S, et al. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett. 1997;233(2–3):125–128. doi: 10.1016/S0304-3940(97)00649-6</mixed-citation><mixed-citation xml:lang="ru">Togari A., Arai M., Mizutani S., et al. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells // Neurosci Lett. 1997. Vol. 233, № 2–3. Р. 125–128. doi: 10.1016/S0304-3940(97)00649-6</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Bajayo A, Bar A, Denes A, et al. Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proceedings of the National Academy of Sciences of the United States of America. 2012;38(109):15455–15460. doi: 10.1073/pnas.1206061109</mixed-citation><mixed-citation xml:lang="ru">Bajayo A., Bar A., Denes A., et al. Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual // Proceedings of the National Academy of Sciences of the United States of America. 2012. Vol. 38, № 109. Р. 15455–15460. doi: 10.1073/pnas.1206061109</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Pierroz DD, Bonnet N, Bianchi EN, et al. Deletion of β-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation. J Bone Miner Res. 2012;27(6):1252–1262. doi: 10.1002/jbmr.1594</mixed-citation><mixed-citation xml:lang="ru">Pierroz D.D., Bonnet N., Bianchi E.N., et al. Deletion of β-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation // J Bone Miner Res. 2012. Vol. 27, № 6. Р. 1252–1262. doi: 10.1002/jbmr.1594</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Kliemann K, Kneffel M, Bergen I, et al. Quantitative analyses of bone composition in acetylcholine receptor M3R and alpha7 knockout mice. Life Sci. 2012;91(21–22):997–1002. doi: 10.1016/j.lfs.2012.07.024</mixed-citation><mixed-citation xml:lang="ru">Kliemann K., Kneffel M., Bergen I., et al. Quantitative analyses of bone composition in acetylcholine receptor M3R and alpha7 knockout mice // Life Sci. 2012. Vol. 91, № 21–22. Р. 997–1002. doi: 10.1016/j.lfs.2012.07.024</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Elefteriou F. Impact of the Autonomic Nervous System on the Skeleton. Physiol Rev. 2018;98(3):1083–1112. doi: 10.1152/physrev.00014.2017</mixed-citation><mixed-citation xml:lang="ru">Elefteriou F. Impact of the Autonomic Nervous System on the Skeleton // Physiol Rev. 2018. Vol. 98, № 3. Р. 1083–1112. doi: 10.1152/physrev.00014.2017</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Jimenez-Andrade JM, Mantyh PW. Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther. 2012;14(3):R101. doi: 10.1186/ar3826</mixed-citation><mixed-citation xml:lang="ru">Jimenez-Andrade J.M., Mantyh P.W. Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice // Arthritis Res Ther. 2012. Vol. 14, № 3. Р. R101. doi: 10.1186/ar3826</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 2012;64(7):2223–2232. doi: 10.1002/art.34385</mixed-citation><mixed-citation xml:lang="ru">Ghilardi J.R., Freeman K.T., Jimenez-Andrade J.M., et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint // Arthritis Rheum. 2012. Vol. 64, № 7. Р. 2223–2232. doi: 10.1002/art.34385</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Castañeda-Corral G, Jimenez-Andrade JM, Bloom AP, et al. The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience. 2011;178:196–207. doi: 10.1016/j.neuroscience.2011.01.039</mixed-citation><mixed-citation xml:lang="ru">Castañeda-Corral G., Jimenez-Andrade J.M., Bloom A.P., et al. The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A // Neuroscience. 2011. Vol. 178. Р. 196–207. doi: 10.1016/j.neuroscience.2011.01.039</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Nencini S, Ringuet M, Kim D-H, Greenhill C, Ivanusic JJ. GDNF, neurturin, and artemin activate and sensitize bone afferent neurons and contribute to inflammatory bone pain. J Neurosci. 2018;38(21):4899–4911. doi: 10.1523/JNEUROSCI.0421-18.2018</mixed-citation><mixed-citation xml:lang="ru">Nencini S., Ringuet M., Kim D.-H., Greenhill C., Ivanusic J.J. GDNF, neurturin, and artemin activate and sensitize bone afferent neurons and contribute to inflammatory bone pain // J. Neurosci. 2018. Vol. 38, № 21. Р. 4899–4911. doi: 10.1523/JNEUROSCI.0421-18.2018.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone. 2011;48(2):389–398. doi: 10.1016/j.bone.2010.09.019</mixed-citation><mixed-citation xml:lang="ru">Ghilardi J.R., Freeman K.T., Jimenez-Andrade J.M., et al. Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers // Bone. 2011. Vol. 48, № 2. Р. 389–398. doi: 10.1016/j.bone.2010.09.019</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">McMahon SB, La Russa F, Bennett DLH. Crosstalk between the nociceptive and immune systems in host defence and disease. Nat Rev Neurosci. 2015;16(7):389–402. doi: 10.1038/nrn3946</mixed-citation><mixed-citation xml:lang="ru">McMahon S.B., La Russa F., Bennett D.L.H. Crosstalk between the nociceptive and immune systems in host defence and disease // Nat Rev Neurosci. 2015. Vol. 16, № 7. Р. 389–402. doi: 10.1038/nrn3946</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Tao R, Mi B, Hu Y, et al. Hallmarks of peripheral nerve function in bone regeneration. Bone Res. 2023;11(1):6. doi: 10.1038/s41413-022-00240-x</mixed-citation><mixed-citation xml:lang="ru">Tao R., Mi B., Hu Y., et al. Hallmarks of peripheral nerve function in bone regeneration // Bone Res. 2023. Vol. 11, № 1. Р. 6. doi: 10.1038/s41413-022-00240-x</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Mi J, Xu J, Yao H, et al. Calcitonin gene-related peptide enhances distraction osteogenesis by increasing angiogenesis. Tissue Eng. 2021;27(1–2):87–102. doi: 10.1089/ten.TEA.2020.0009</mixed-citation><mixed-citation xml:lang="ru">Mi J., Xu J., Yao H., et al. Calcitonin gene-related peptide enhances distraction osteogenesis by increasing angiogenesis // Tissue Eng. 2021. Vol. 27, № 1–2. Р. 87–102. doi: 10.1089/ten.TEA.2020.0009</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Wang L, Shi X, Zhao R, et al. Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption. Bone. 2010;46(5):1369–1379. doi: 10.1016/j.bone.2009.11.029</mixed-citation><mixed-citation xml:lang="ru">Wang L. Shi X., Zhao R., et al. Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption // Bone. 2010. Vol. 46, № 5. Р. 1369–1379. doi: 10.1016/j.bone.2009.11.029</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Yuan Y, Jiang Y, Wang B, et al. Deficiency of calcitonin gene-related peptide affects macrophage polarization in osseointegration. Front Physiol. 2020;11:733. doi: 10.3389/fphys.2020.00733</mixed-citation><mixed-citation xml:lang="ru">Yuan Y., Jiang Y., Wang B., et al. Deficiency of calcitonin gene-related peptide affects macrophage polarization in osseointegration // Front. Physiol. 2020. Vol. 11. Р. 733. doi: 10.3389/fphys.2020.00733</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Pongratz G, Straub RH. Role of peripheral nerve fibres in acute and chronic inflammation in arthritis. Nat Rev Rheumatol. 2013;9(2):117–126. doi: 10.1038/nrrheum.2012.181</mixed-citation><mixed-citation xml:lang="ru">Pongratz G., Straub R.H. Role of peripheral nerve fibres in acute and chronic inflammation in arthritis // Nat Rev Rheumatol. 2013. Vol. 9, № 2. Р. 117–126. doi: 10.1038/nrrheum.2012.181</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Vinik AI, Nevoret M-L, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747–787. doi: 10.1016/j.ecl.2013.06.001</mixed-citation><mixed-citation xml:lang="ru">Vinik A.I., Nevoret M.-L., Casellini C., Parson H. Diabetic neuropathy // Endocrinol Metab Clin North Am. 2013. Vol. 42, № 4. Р. 747–787. doi: 10.1016/j.ecl.2013.06.001</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Van Maanen MA, Vervoordeldonk MJ, Tak PP. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(4):229–232. doi: 10.1038/nrrheum.2009.31</mixed-citation><mixed-citation xml:lang="ru">Van Maanen M.A., Vervoordeldonk M.J., Tak P.P. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis // Nat Rev Rheumatol. 2009. Vol. 5, № 4. Р. 229–232. doi: 10.1038/nrrheum.2009.31</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Ha J, Hester T, Foley R, et al. Charcot foot reconstruction outcomes: A systematic review. J Clin Orthop Trauma. 2020;11(3):357–368. doi: 10.1016/j.jcot.2020.03.025</mixed-citation><mixed-citation xml:lang="ru">Ha J., Hester T., Foley R., et al. Charcot foot reconstruction outcomes: A systematic review // J Clin Orthop Trauma. 2020. Vol. 11, № 3. Р. 357–368. doi: 10.1016/j.jcot.2020.03.025</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Kwaadu KY. Charcot Reconstruction: Understanding and Treating the Deformed Charcot Neuropathic Arthropathic Foot. Clin Podiatr Med Surg. 2020;37(2):247–261. doi: 10.1016/j.cpm.2019.12.002</mixed-citation><mixed-citation xml:lang="ru">Kwaadu K.Y. Charcot Reconstruction: Understanding and Treating the Deformed Charcot Neuropathic Arthropathic Foot // Clin Podiatr Med Surg. 2020. Vol. 37, № 2. Р. 247–261. doi: 10.1016/j.cpm.2019.12.002</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Young RJ. The Organisation of Diabetic Foot Care: Evidence-Based Recommendations. The Foot in Diabetes. John Wiley &amp; Sons, Ltd; 2006. Р. 398–403. doi: 10.1002/0470029374.ch36</mixed-citation><mixed-citation xml:lang="ru">Young R.J. The Organisation of Diabetic Foot Care: Evidence-Based Recommendations. The Foot in Diabetes. John Wiley &amp; Sons, Ltd, 2006. Р. 398–403. doi: 10.1002/0470029374.ch36</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Siddiqui NA, Millonig KJ, Mayer BE, et al. Increased Arthrodesis Rates in Charcot Neuroarthropathy Utilizing Distal Tibial Distraction Osteogenesis Principles. Foot &amp; Ankle Specialist. 2022;15(4):394–408. doi: 10.1177/19386400221087822</mixed-citation><mixed-citation xml:lang="ru">Siddiqui N.A., Millonig K.J., Mayer B.E., et al. Increased Arthrodesis Rates in Charcot Neuroarthropathy Utilizing Distal Tibial Distraction Osteogenesis Principles // Foot &amp; Ankle Specialist. 2022. Vol. 15, № 4. Р. 394–408. doi: 10.1177/19386400221087822</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Tellisi N, Fragomen AT, Ilizarov S, Rozbruch SR. Limb Salvage Reconstruction of the Ankle with Fusion and Simultaneous Tibial Lengthening Using the Ilizarov/Taylor Spatial Frame. HSS Journal. 2007;4(1):32–42. doi: 10.1007/s11420-007-9073-0</mixed-citation><mixed-citation xml:lang="ru">Tellisi N., Fragomen A.T., Ilizarov S., Rozbruch S.R. Limb Salvage Reconstruction of the Ankle with Fusion and Simultaneous Tibial Lengthening Using the Ilizarov/Taylor Spatial Frame // HSS Journal. 2007. Vol. 4, № 1. Р. 32–42. doi: 10.1007/s11420-007-9073-0</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Sakurakichi K, Tsuchiya H, Uehara K, et al. Ankle arthrodesis combined with tibial lengthening using the Ilizarov apparatus. Journal of Orthopaedic Science. 2003;8(1):20–25. doi: 10.1007/s007760300003</mixed-citation><mixed-citation xml:lang="ru">Sakurakichi K., Tsuchiya H., Uehara K., et al. Ankle arthrodesis combined with tibial lengthening using the Ilizarov apparatus // Journal of Orthopaedic Science. 2003. Vol. 8, № 1. Р. 20–25. doi: 10.1007/s007760300003</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Millonig KJ, Siddiqui NA. Tibial Lengthening and Intramedullary Nail Fixation for Hindfoot Charcot Neuroarthropathy. Clin Podiatr Med Surg. 2022;39(4):659–673. doi: 10.1016/j.cpm.2022.05.011</mixed-citation><mixed-citation xml:lang="ru">Millonig K.J., Siddiqui N.A. Tibial Lengthening and Intramedullary Nail Fixation for Hindfoot Charcot Neuroarthropathy // Clin Podiatr Med Surg. 2022. Vol. 39, № 4. Р. 659–673. doi: 10.1016/j.cpm.2022.05.011</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Galli M, Pitocco D, Ruotolo V, et al. The effect of alendronate in acute charcot neuroarthropathy of the foot could be mediated by the decrease of IGF-1. Orthop Procs. 2009;91-B(suppl.):161–161. doi: 10.1302/0301-620X.91BSUPP_I.0910161c</mixed-citation><mixed-citation xml:lang="ru">Galli M., Pitocco D., Ruotolo V., et al. The effect of alendronate in acute charcot neuroarthropathy of the foot could be mediated by the decrease of IGF-1 // Orthop Procs. 2009. Vol. 91-B, suppl. Р. 161–161. doi: 10.1302/0301-620X.91BSUPP_I.0910161c</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Shina Y, Engebretsen L, Iwasa J, et al. Use of bisphosphonates for the treatment of stress fractures in athletes. Knee Surg Sports Traumatol Arthrosc. 2011;17(5):542–550. doi: 10.1007/s00167-008-0673-0</mixed-citation><mixed-citation xml:lang="ru">Shina Y., Engebretsen L., Iwasa J., et al. Use of bisphosphonates for the treatment of stress fractures in athletes // Knee Surg Sports Traumatol Arthrosc. 2011. Vol. 17, № 5. Р. 542–550. doi: 10.1007/s00167-008-0673-0</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Rastogi A, Hajela A, Prakash M, et al. Teriparatide (recombinant human parathyroid hormone) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double-blind placebo-controlled study. J Diabetes. 2019;11(9):703–710. doi: 10.1111/1753-0407.12902</mixed-citation><mixed-citation xml:lang="ru">Rastogi A., Hajela A., Prakash M., et al. Teriparatide (recombinant human parathyroid hormone) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double-blind placebo-controlled study // J Diabetes. 2019. Vol. 11, № 9. Р. 703–710. doi: 10.1111/1753-0407.12902</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Petrova NL, Donaldson NK, Bates M, et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care. 2021;44(7):1613–1621. doi: 10.2337/dc21-0008</mixed-citation><mixed-citation xml:lang="ru">Petrova N.L., Donaldson N.K., Bates M., et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study // Diabetes Care. 2021. Vol. 44, № 7. Р. 1613–1621. doi: 10.2337/dc21-0008</mixed-citation></citation-alternatives></ref></ref-list></back></article>
